Clexio Biosciences
Elisabeth Kogan has a diverse work experience in the biotech and pharmaceutical industries. Elisabeth co-founded Clexio Biosciences in 2018 and currently serves as the CEO. Prior to this, they worked at Teva Pharmaceuticals for many years, holding various high-level positions such as SVP InnoTech (Innovation & Technologies) from 2016 to 2018, SVP Global Generic R&D from 2010 to 2015, and VP Global Portfolio Strategy from 2009 to 2010. Elisabeth was also a Board Member at École Polytechnique from 2013 to 2018. Before joining Teva, they worked at Teva Pharmaceuticals as the VP Sales & Marketing - TAPI from 2002 to 2008. Elisabeth began their career in the pharmaceutical industry at sanofi-aventis in 1996, where they worked in process development.
Elisabeth Kogan obtained their MA in Sciences and Business from CentraleSupélec from 1993 to 1996. Prior to that, they attended classes préparatoires Chaptal from 1991 to 1993, where they studied mathematics, physics, and chemistry.
This person is not in any offices
Clexio Biosciences
Clexio Biosciences is a CNS-first clinical-stage pharmaceutical company. Our therapies are designed to address patients’ unmet needs through scientifically based integration of drugs with innovative technologies. Clexio’s growing pipeline is focused on the development of safe and effective treatments with rapid onset of action for a wide range of neurological and psychiatric conditions, including Major Depressive Disorder, Parkinson’s Disease, Pain and other conditions involving impairment of the neurological system. Patients, and what they are living with, are at the center of everything we do. Our passion is to find ways to help patients regain a sense of balance, health and a life worth living. Clexio’s team is comprised of a multi-disciplinary team with vast experience in drug development. We see our team and our partners as the key ingredients to our success. Join our vision to make lives of millions of patients worth living again.